Development of interferon γ-based immunocytokines targeting renal cancer.
Advanced renal cancer is an incurable malignancy in need of novel therapeutic avenues. We have generated interferon γ (IFNγ)-based fusion antibodies (immunocytokines) that target CD70, a putative biomarker of renal cancer. These immunocytokines efficiently labeled renal cancer cells, and, when combined with the proteasome inhibitor bortezomib, killed them by activating a RIP1-dependent necrotic pathway.
Immune Cell Development and Host Defense Program; Fox Chase Cancer Center; Philadelphia, PA USA.
Peirong
P
Chen
Siddharth
S
Balachandran
CD70; RIP1; immunocytokines; interferon; necroptosis; necrosis; renal cell carcinoma